Enterprise Value

772.4M

Cash

106.5M

Avg Qtr Burn

-59.74M

Short % of Float

22.28%

Insider Ownership

6.72%

Institutional Own.

83.81%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VOWST (SER-109) Details
Bacterial infection, Clostridioides difficile infection

Approved

Quarterly sales

SER-287 Details
Inflammatory bowel disease, Ulcerative colitis

Phase 2b

Update

SER-301 Details
Inflammatory bowel disease, Ulcerative colitis

Phase 1b

Data readout

SER-155 Details
Graft-versus-host disease , Intestinal infection

Phase 1b

Data readout

SER-401 Details
Melanoma, Cancer

Failed

Discontinued